Joint Clinical Assessment Poster Tour

Speaker(s)

Kejsi Begaj, PharmD, Center for Health Outcomes, Policy, and Economics, Rutgers University, New Brunswick, NJ, USA and Alin Kalayjian, PharmD, MBA, GSK, Somerset, NJ, USA

Posters Featured in this Tour:

PT25 Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

PT26 From Clinical Assessment to Drug Reimbursement in Spain: Current Timelines and Potential Impact From the Joint Clinical Assessment

PT27 Time to Reimbursement in Ireland: Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines

PT28 Do We Say “Game Over” When OS Data Is Not Mature at Launch? A Review of Value Drivers for Oncology Products in the Absence of Significant OS Gains

PT29 From European Union Joint Clinical Assessments to Local Health Technology Assessments: An Environmental Scan of Methodological Guidance Across Key European Markets

PT30 Navigating the New European Member State Coordination Group on Health Technology Assessment Quantitative Evidence Synthesis Guidelines

Code

213